Yousif Capital Management LLC Has $4.20 Million Holdings in Exelixis, Inc. $EXEL

Yousif Capital Management LLC cut its stake in Exelixis, Inc. (NASDAQ:EXEL) by 4.7% in the second quarter, Holdings Channel.com reports. The firm owned 95,256 shares of the biotechnology company’s stock after selling 4,669 shares during the quarter. Yousif Capital Management LLC’s holdings in Exelixis were worth $4,198,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. Nuveen LLC acquired a new position in Exelixis in the 1st quarter worth $123,310,000. AQR Capital Management LLC lifted its position in Exelixis by 73.8% during the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after buying an additional 2,926,884 shares in the last quarter. Invesco Ltd. lifted its position in Exelixis by 40.2% during the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after buying an additional 1,596,948 shares in the last quarter. Jupiter Asset Management Ltd. lifted its position in Exelixis by 233.4% during the 1st quarter. Jupiter Asset Management Ltd. now owns 1,400,270 shares of the biotechnology company’s stock worth $51,698,000 after buying an additional 980,319 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its position in Exelixis by 935.4% during the 1st quarter. Pacer Advisors Inc. now owns 678,067 shares of the biotechnology company’s stock worth $25,034,000 after buying an additional 612,577 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several analyst reports. Truist Financial cut their price target on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. Stephens raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $29.00 to $60.00 in a research report on Tuesday, June 24th. The Goldman Sachs Group initiated coverage on shares of Exelixis in a research report on Wednesday, September 17th. They set a “buy” rating and a $47.00 price target on the stock. Wall Street Zen raised shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Finally, Guggenheim reaffirmed a “buy” rating and issued a $45.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Fifteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.42.

Exelixis Stock Performance

Shares of EXEL stock opened at $40.03 on Thursday. The firm’s 50-day moving average is $38.75 and its 200-day moving average is $39.96. The stock has a market cap of $10.78 billion, a price-to-earnings ratio of 19.25, a PEG ratio of 0.79 and a beta of 0.38. Exelixis, Inc. has a 52-week low of $27.86 and a 52-week high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million for the quarter, compared to analysts’ expectations of $574.36 million. During the same period in the prior year, the firm earned $0.84 EPS. Exelixis’s quarterly revenue was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Sell-side analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.